FamiCord
Group
FamiCord is a trusted group of cell and tissue banks, operating in more than 34 countries with 15 of its own laboratories⁽¹⁾. Present in Europe since 1997, FamiCord Group is trusted by hundreds of thousands of families worldwide and stores approximately 1.5 million units of biological material.
More than a stem-cell bank
FamiCord Group is more than a stem cell bank, with Europe’s most extensive experience in releasing cord blood units for life-saving medical procedures, we go far beyond the collection and storage of biological material. In our cell-based Advanced Therapy Medicinal Product (ATMP) manufacturing facilities, we also manufacture products for cell therapies. By combining our expertise in partnering transplant clinics with advanced pharmaceutical manufacturing, we help translate scientific innovation into new therapeutic opportunities for patients⁽²⁾.
Working closely with physicians, researchers and transplant centres, FamiCord Group has released more than 8,500 cellular products for clinical use, supporting the treatment of patients across a wide range of conditions.
These products originate from various cell sources, including peripheral blood, bone marrow and umbilical cord blood.
Total FamiCord Cellular Therapy Products Released — till 19.11.2026
| Cell source | Number of products |
|---|---|
| Peripheral blood – hematopoietic stem cells | 5125 |
| Bone marrow – hematopoietic stem cells | 1321 |
| Umbilical cord blood (incl. placental blood) | 295 |
| Umbilical cord – mesenchymal cells | 2031 |
| CAR-T | 11 |
| Other types (incl. adipose tissue & skeletal muscle) | 122 |
| TOTAL | 8905 |
What this means for families storing cord blood and cord tissue
By choosing FamiCord, you can be confident that your child’s cord blood and cord tissue are stored to the highest quality standards required for clinical use. Ability to produce advanced therapy medicinal products (ATMPs) for our clients, opens up our clients to benefit from potential cell-based treatments where medically appropriate and legally authorised.
The Group has released 295 umbilical-cord/placental blood applications, together with 2031 releases of umbilical-cord mesenchymal cells (from cord tissue).
Umbilical cord blood applications
| Umbilical cord blood applications | Uses |
|---|---|
| Autologous (the child’s own sample) | 158 |
| Allogeneic | 137 |
| Total cord-blood applications | 295 |
Of the 295 cord blood uses within FamiCord Group, 158 were autologous – meaning patients received their own previously stored stem cells. The remaining 137 were allogeneic, meaning stem cells from a donor were used.
Autologous use requires access to the patient’s own previously collected and stored stem cells. Not all patients have this option, which affects the availability of this type of treatment
Allogeneic use involves stem cells from another person, including a related donor. For certain genetic and hematological diseases, a patient’s own stem cells may not be suitable for treatment because they may carry the same underlying condition. In such cases, stem cells from a suitable donor, such as a sibling, may be an important alternative⁽³⁾.